CervoMed Announces Presentation Of Biomarker Data From The AscenD-LB Phase 2a Trial And Preclinical Data Supporting Potential Of Neflamapimod In Tau-Mediated Disease At AD/PD 2024
CervoMed Announces Presentation Of Biomarker Data From The AscenD-LB Phase 2a Trial And Preclinical Data Supporting Potential Of Neflamapimod In Tau-Mediated Disease At AD/PD 2024
CervoMED 宣佈在 2024 年 AD/PD 上公佈來自 Ascend-LB 2a 期試驗的生物標誌物數據和支持奈弗拉匹莫德在陶介導疾病中的潛力的臨床前數據
- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP)
-與安慰劑相比，奈弗拉匹莫德導致血漿膠質纖維酸性蛋白（GFAP）水平顯著降低
- Neflamapimod effects on GFAP correlated to clinical outcomes assessed by CDR Sum of Boxes (CDR-SB)
- 奈弗拉匹莫德對 GFAP 的影響與 CDR Boxes Sum of Boxes (CDR-SB) 評估的臨床結果相關
- Scientific collaborators from University College London (UCL) present data demonstrating neflamapimod improves axonal transport in a transgenic mouse model of frontotemporal dementia (FTD)
-倫敦大學學院（UCL）的科學合作者提供的數據表明，奈弗拉馬莫德改善了額葉癡呆（FTD）轉基因小鼠模型的軸突轉移
BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies...
波士頓，2024年3月5日（GLOBE NEWSWIRE）——專注於開發腦退行性疾病治療...
登入免費觀看全文
登入/註冊